Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical (ISRG) senior vice president Iman Jeddi reported routine equity vesting and tax withholding transactions. On February 10, 2026, 838 restricted stock units granted on February 10, 2023 converted into 838 shares of common stock at an exercise price of $0.0.
A portion of these shares—309—was automatically withheld at a value of $492.84 per share to cover statutory taxes, leaving 585 shares held directly after the transactions. In addition, 26,649 shares of Intuitive Surgical common stock are reported as held indirectly by a trust associated with the reporting person. The RSU award vests 25% annually over four years, with each vested RSU converting into one share of common stock.
Intuitive Surgical EVP & CFO Jamie Samath reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) converted into 1,077 shares of common stock at an exercise price of $0.0, increasing his directly held shares to 8,295 before tax withholding.
On the same date, 496 common shares were withheld at $492.84 per share to cover statutory taxes, leaving 7,799 common shares owned directly afterward. The RSUs vest 25% per year over four years starting on each anniversary of February 10, 2023, with each RSU delivering one share of common stock when it vests, subject to continued service.
Intuitive Surgical EVP Henry L. Charlton reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) vested and converted into common shares at $0.0 per share. To cover statutory taxes, 492 shares were surrendered at $492.84 per share, leaving 3,697 common shares held directly and 1,077 RSUs outstanding. The RSU award vests in 25% annual installments on each anniversary of February 10, 2023, contingent on continued service.
Intuitive Surgical executive Mark Brosius reported routine equity compensation activity. On February 10, 2026, 838 restricted stock units granted on February 28, 2023 converted into the same number of common shares at an exercise price of $0.00.
To cover statutory tax withholding, 433 common shares were automatically disposed of at $492.84 per share, leaving Brosius with 592 shares of Intuitive Surgical common stock held directly after the transactions. The RSUs vest in four equal annual installments, each representing 25% of the award.
Intuitive Surgical senior executive Iman Jeddi filed an initial statement of ownership, detailing equity awards and indirect common stock holdings. As of January 29, 2026, a trust associated with Jeddi held 26,649 shares of Intuitive Surgical common stock. Jeddi also directly holds several non-qualified stock options and stock units. These include options to buy 5,625, 3,760, 5,028, 3,760 and 5,028 shares of common stock at exercise prices ranging from $76.9989 to $304.67 per share, with expirations between August 2026 and August 2030. The filing further lists performance stock units of 2,702 and 5,585 shares for which performance criteria have been achieved, vesting in 2027 and 2026, and multiple restricted stock unit grants totaling several thousand shares that vest over a four-year schedule.
Intuitive Surgical executive Patricia L. Wadors, SVP and Chief Human Resources Officer, filed an initial ownership report showing she directly holds two blocks of restricted stock units (RSUs) in Intuitive Surgical common stock. One award covers 6,419 RSUs that vest 25% each year on October 10 starting in 2024, and another covers 1,831 RSUs that vest 25% each year on February 26 starting in 2025. Each RSU converts into one share of common stock when it vests, conditioned on her continued service with the company.
Intuitive Surgical provides robotic-assisted systems, instruments, services, and digital tools that support minimally invasive care, led by its da Vinci surgical platforms and Ion lung biopsy system. The company focuses on improving patient outcomes, care-team experience, access to care, and total cost per treatment episode.
Its ecosystem includes stapling and energy instruments, training pathways, simulation (SimNow), analytics (Custom Hospital Analytics, My Intuitive), and comprehensive field service. For the year ended December 31, 2025, domestic revenue represented 68% of total revenue, with 32% generated outside the U.S. The company highlights extensive business, regulatory, and technology risks, including intense competition, global macroeconomic pressures, supply chain dependence, evolving data and AI regulations, and complex FDA and international compliance obligations.
Intuitive Surgical director Keith R. Leonard reported a change in his holdings of Intuitive Surgical, Inc. common stock. On 01/29/2026, 369 shares of common stock were transferred at a price of $0.0 per share, coded as transaction type "J" for “other.”
The footnote explains this was a transfer of shares pursuant to a divorce decree, indicating a personal, court-directed reallocation rather than an open‑market trade. After this transaction, Leonard beneficially owns 370 shares of Intuitive Surgical common stock in direct form.
Intuitive Surgical executive Mark Brosius reported new performance-based equity awards. On January 28, 2026, he was credited with 2,702 performance stock units tied to a grant dated February 26, 2024 and 5,585 performance stock units tied to a grant dated February 28, 2023.
The company’s compensation committee determined the performance criteria for both awards had been achieved. The 2024-related units are scheduled to vest on February 26, 2027, and the 2023-related units on February 28, 2026, in each case requiring Brosius to remain in continuous service until those vesting dates.
Intuitive Surgical executive Gary Loeb reported performance-based equity awards. On January 28, 2026, he acquired 2,543 performance stock units tied to a February 26, 2024 grant and 2,098 performance stock units tied to a February 28, 2023 grant, each at a stated price of 0.0 per unit.
The company’s compensation committee determined that required performance goals were achieved. The 2023-related units are scheduled to vest on February 28, 2026, and the 2024-related units on February 26, 2027, in each case contingent on Loeb’s continued service with Intuitive Surgical.